Elan Hahn

Elan Hahn

Auto-generated profile, based on publicly available information

Elan Hahn

Department of Pathology and Laboratory Medicine, Sinai Health System, Toronto, ON, Canada.

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Human Pathology
Verified
Journal Article
Closed access
CWChiyun Wang
Chiyun Wang
EHElan Hahn
Elan Hahn
ESElzbieta Slodkowska
Elzbieta Slodkowska
AEAntoine Eskander
Antoine Eskander
DEDanny Enepekides
Danny Enepekides
BXBin Xu
Bin Xu

21 May 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
EHElan Hahn
Elan Hahn
JPJuan Putra
Juan Putra
Hepatocellular adenoma in the paediatric population: Molecular classification and clinical associations

17 August 2023 in Laboratory Investigation
Verified
Journal Article
Closed access
EHElan Hahn
Elan Hahn
BXBin Xu
Bin Xu
NKNora Katabi
Nora Katabi
SDSnjezana Dogan
Snjezana Dogan
SSStephen M. Smith
Stephen M. Smith
JBJustin A. Bishop
Justin A. Bishop

18 May 2018 in Histopathology
Verified
Journal Article
Closed access
PDF file
FBFadi Brimo
Fadi Brimo
Michelle R. DownesMichelle R. Downes
Michelle R. Downes
TJTamara Jamaspishvili
Tamara Jamaspishvili
DBDavid Berman
David Berman
GBGuliz A Barkan
Guliz A Barkan
Kiril TrpkovKiril Trpkov
Kiril Trpkov

26 September 2018 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
EHElan Hahn
Elan Hahn
SLStanley K Liu
Stanley K Liu
DVDanny Vesprini
Danny Vesprini
BXBin Xu
Bin Xu
Michelle R. DownesMichelle R. Downes
Michelle R. Downes
Tumour-induced immunosuppression plays a role in the development and progression of cancer. Of interest is the interaction between programmed death-1 and programmed death ligand-1 (PD-L1) which can be targeted through immune checkpoint blockade; however, there are limited data surrounding the composition of the immune milieu in prostate cancer. We preliminarily assessed 21 radical prostatectomies in therapy-naïve patients for immune markers and PD-L1 expression. The immune infiltrates were higher in adenocarcinoma than benign prostate (lymphocytes p<0.001, macrophages p=0.010) with 5% of cases being PD-L1 high (≥5% expression). Increased peritumoural CD68 and CD163 expression correlated with lower grade group (GG) (p=0.024 and p=0.014, respectively) with a trend towards increased CD68 expression in lower stage cases (p=0.086). There was also increased CD45 expression in lower GGs (p=0.063). We found the immune infiltrate in acinar prostate cancer to be extremely heterogeneous with an overall immunophenotype unlikely to respond to immune checkpoint blockade.

30 October 2024 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
EHElan Hahn
Elan Hahn
IWIlan Weinreb
Ilan Weinreb
RSRaja R. Seethala
Raja R. Seethala
EOEsther MD O’Regan
Esther MD O’Regan
DBDaniel Baumhoer
Daniel Baumhoer
JBJustin A. Bishop
Justin A. Bishop
Sialadenoma papilliferum is a tumor characterized by surface papillary projections and glandular/microcystic proliferation at the lesion base. Cases in which surface involvement is absent have been termed “sialadenoma papilliferum-like intraductal papillary tumor.” Similar tumors that are present in the mandible have been termed “tubulopapillary hidradenoma-like tumor of the mandible.” While previously considered benign, these tumors demonstrate variable clinical behavior and likely exist on a spectrum, rather than as discrete entities. In this study, we present a detailed clinicopathologic and molecular analysis of these lesions and propose a unifying diagnostic term: sialadenopapillary ductal tumor (SDT). Twenty-two cases with similar histologic features were reviewed, with special attention being paid to the clinicopathologic features. Immunohistochemistry for BRAF V600E and molecular testing were performed where material was available. The cases had varying diagnoses, ranging from benign to malignant. Six cases involved bone, 1 of which metastasized to a local lymph node. Of the 20 cases tested for BRAF V600E by immunohistochemistry, 18 were positive. Molecular testing was performed in 5 cases, where BRAF, PTPN11, and PIK3CA mutations were identified, predominantly members of the RAS-RAF-MEK-ERK pathway. In addition, 1 case was reclassified as an intraductal carcinoma after the identification of an NCOA4::RET gene fusion. Tumors on the SDT spectrum all share morphologic and molecular commonalities with unreliable distinguishing features. These tumors demonstrate the potential for aggressive local growth and regional metastasis. We propose a unifying diagnostic term for these lesions to reflect their common morphologic and molecular features and, most importantly, low malignant potential.